CNTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.80%

Insider Buying (Last 12 Months): $107,206.40

Insider Selling (Last 12 Months): $0.00

Context Therapeutics Insider Trading History Chart

Context Therapeutics Share Price & Price History

^$1.03

▼ -0.06 (-5.50%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Context Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/9/2025	Martin A. Lehr	CEO	Buy	100,000	$0.70	$70,000.00	920,190
6/6/2025	Alex C. Levit	Insider	Buy	20,000	$0.58	$11,600.00	29,000
6/6/2025	Jennifer Lynn Minai-Azary	CFO	Buy	40,010	$0.64	$25,606.40	80,010
2/21/2023	Martin A. Lehr	CEO	Buy	5,823	$0.84	$4,891.32	159,701
2/13/2023	Martin A. Lehr	CEO	Buy	5,606	$0.87	$4,877.22	153,878
2/6/2023	Martin A. Lehr	CEO	Buy	5,040	$0.97	$4,888.80	148,272
1/30/2023	Martin A. Lehr	CEO	Buy	7,027	$0.70	$4,918.90	143,232
1/23/2023	Martin A. Lehr	CEO	Buy	6,839	$0.72	$4,924.08	136,205
1/17/2023	Martin A. Lehr	CEO	Buy	6,783	$0.74	$5,019.42	129,366
12/16/2022	Jennifer Lynn Minai-Azary	CFO	Buy	25,000	$0.74	$18,500.00	40,000
12/9/2022	Alex C. Levit	Insider	Buy	6,000	$0.85	$5,100.00	9,000

SEC Filings (Institutional Ownership Changes) for Context Therapeutics (NASDAQ:CNTX)

14.03% of Context Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Context Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/17/2025	Qube Research & Technologies Ltd	82,111	$80K	0.0%	-23.1%	0.089%
11/17/2025	Nantahala Capital Management LLC	1,661,950	$1.61M	0.1%	-14.1%	1.809%
11/17/2025	Citadel Advisors LLC	103,363	$100K	0.0%	N/A	0.112%
11/7/2025	Vanguard Group Inc.	3,495,031	$3.39M	0.0%	+4.0%	3.896%
10/23/2025	Clear Harbor Asset Management LLC	92,804	$90K	0.0%	+60.5%	0.103%
8/14/2025	Qube Research & Technologies Ltd	106,779	$70K	0.0%	-38.7%	0.119%
8/13/2025	Affinity Asset Advisors LLC	518,025	$0.34M	0.0%	-21.6%	0.578%
8/13/2025	Walleye Capital LLC	132,786	$87K	0.0%	-21.4%	0.148%
5/16/2025	Ally Bridge Group NY LLC	1,157,448	$0.71M	0.6%	-26.6%	1.290%
5/15/2025	Landscape Capital Management L.L.C.	41,216	$25K	0.0%	-54.2%	0.046%
5/14/2025	Affinity Asset Advisors LLC	660,589	$0.40M	0.0%	-34.9%	0.736%
2/17/2025	Velan Capital Investment Management LP	90,000	$94K	0.1%	-93.0%	0.120%
2/17/2025	Shay Capital LLC	50,000	$52K	0.0%	N/A	0.067%
2/17/2025	MPM Bioimpact LLC	14,705,882	$15.44M	2.2%	N/A	19.608%
2/17/2025	Millennium Management LLC	178,718	$0.19M	0.0%	+24.2%	0.238%
2/17/2025	Citadel Advisors LLC	29,900	$31K	0.0%	N/A	0.040%
2/17/2025	Allostery Investments LP	950,166	$1M	1.0%	N/A	1.267%
2/17/2025	Ally Bridge Group NY LLC	1,576,762	$1.66M	1.4%	-10.3%	2.102%
2/14/2025	Jane Street Group LLC	27,395	$29K	0.0%	N/A	0.037%
2/14/2025	Northern Trust Corp	113,565	$0.12M	0.0%	-34.2%	0.151%
2/14/2025	Blue Owl Capital Holdings LP	6,357,928	$6.68M	1.6%	+17.5%	8.477%
2/13/2025	Marshall Wace LLP	203,286	$0.21M	0.0%	N/A	0.271%
2/13/2025	Affinity Asset Advisors LLC	1,015,340	$1.07M	0.1%	-23.1%	1.354%
2/13/2025	Walleye Capital LLC	166,306	$0.18M	0.0%	+51.7%	0.222%
2/13/2025	Renaissance Technologies LLC	338,435	$0.36M	0.0%	+412.8%	0.451%
2/13/2025	ADAR1 Capital Management LLC	351,094	$0.37M	0.1%	-6.1%	0.468%
2/12/2025	Landscape Capital Management L.L.C.	90,000	$94K	0.0%	N/A	0.120%
2/12/2025	Geode Capital Management LLC	628,729	$0.66M	0.0%	+9.2%	0.838%
2/12/2025	Franklin Resources Inc.	4,003,380	$4.20M	0.0%	+115.9%	5.338%
1/17/2025	Clear Harbor Asset Management LLC	57,804	$61K	0.0%	+60.6%	0.077%
11/27/2024	Franklin Resources Inc.	1,853,988	$3.69M	0.0%	N/A	2.472%
11/16/2024	Geode Capital Management LLC	575,899	$1.13M	0.0%	-6.8%	0.768%
11/15/2024	Y Intercept Hong Kong Ltd	45,635	$89K	0.0%	N/A	0.061%
11/15/2024	State Street Corp	111,907	$0.22M	0.0%	+21.5%	0.149%
11/14/2024	Ally Bridge Group NY LLC	1,757,524	$3.45M	1.8%	-6.8%	2.343%
11/13/2024	Great Point Partners LLC	6,934,982	$13.59M	4.0%	-6.5%	9.247%
8/20/2024	Nantahala Capital Management LLC	1,935,484	$3.88M	0.2%	N/A	2.581%
8/16/2024	Driehaus Capital Management LLC	2,258,065	$4.53M	0.0%	N/A	3.011%
8/15/2024	Blue Owl Capital Holdings LP	5,161,290	$10.35M	2.9%	N/A	6.882%
8/15/2024	Affinity Asset Advisors LLC	1,619,140	$3.25M	0.4%	+392.4%	2.159%
8/14/2024	Great Point Partners LLC	7,419,355	$14.88M	2.8%	N/A	9.893%
8/14/2024	Ally Bridge Group NY LLC	1,886,232	$3.78M	2.3%	+159.8%	2.515%
8/9/2024	Renaissance Technologies LLC	65,200	$0.13M	0.0%	+63.4%	0.087%
5/29/2024	Opaleye Management Inc.	1,108,357	$1.53M	0.3%	+13.7%	1.478%
2/15/2024	Opaleye Management Inc.	975,000	$1.10M	0.3%	N/A	6.107%
11/15/2023	Affinity Asset Advisors LLC	328,817	$0.50M	0.1%	+22.9%	2.059%
8/21/2023	Affinity Asset Advisors LLC	267,574	$0.43M	0.1%	N/A	1.675%
7/21/2023	Clear Harbor Asset Management LLC	36,000	$58K	0.0%	N/A	0.225%
2/16/2023	AIGH Capital Management LLC	1,143,745	$0.75M	0.2%	-11.5%	7.162%
2/14/2023	swisspartners Ltd.	180,000	$0.12M	0.2%	+111.8%	1.127%
11/14/2022	Worth Venture Partners LLC	322,628	$0.36M	0.2%	+8.4%	2.021%
11/1/2022	swisspartners Ltd.	85,000	$94K	0.1%	+101.3%	0.532%
8/13/2022	Virtu Financial LLC	46,445	$98K	0.0%	N/A	0.291%
8/12/2022	Affinity Asset Advisors LLC	883,654	$1.87M	0.8%	+13.6%	5.535%
5/4/2022	swisspartners Ltd.	14,315	$4.98M	3.5%	-66.1%	0.090%
2/14/2022	Altium Capital Management LP	493,531	$1.31M	0.4%	N/A	4.501%
2/11/2022	QCM Cayman Ltd.	14,041	$37K	0.2%	N/A	0.128%
2/10/2022	AIGH Capital Management LLC	762,721	$2.03M	0.6%	N/A	6.955%
2/9/2022	swisspartners Ltd.	42,235	$0.11M	0.1%	N/A	0.385%

Data available starting January 2016

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $1.03

$1.00

$1.10

50 Day Range

MA: $1.16

$0.91

$1.44

52 Week Range

Now: $1.03

$0.49

$1.61

Volume

1,565,710 shs

Average Volume

314,029 shs

Market Capitalization

$94.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.94

Who are the company insiders with the largest holdings of Context Therapeutics?: Context Therapeutics' top insider shareholders include:
Martin A Lehr (CEO)
Jennifer Lynn Minai-Azary (CFO)
Alex C Levit (Insider)
Learn More about top insider investors at Context Therapeutics.
Who are the major institutional investors of Context Therapeutics?: Context Therapeutics' top institutional shareholders include:
Vanguard Group Inc. — 3.90%
Nantahala Capital Management LLC — 1.81%
Citadel Advisors LLC — 0.11%
Clear Harbor Asset Management LLC — 0.10%
Qube Research & Technologies Ltd — 0.09%
Learn More about top institutional investors of Context Therapeutics stock.
Which major investors are selling Context Therapeutics stock?: In the last quarter, CNTX stock was sold by these institutional investors:
Nantahala Capital Management LLC
Qube Research & Technologies Ltd
Which major investors are buying Context Therapeutics stock?: Within the last quarter, CNTX stock was purchased by institutional investors including:
Vanguard Group Inc.
Citadel Advisors LLC
Clear Harbor Asset Management LLC
During the last year, these company insiders have bought Context Therapeutics stock:
Martin A Lehr (CEO)
Jennifer Lynn Minai-Azary (CFO)
Alex C Levit (Insider)
Learn More investors buying Context Therapeutics stock.